Arca
Skip to content
Tools
Tools

Hypercalcemia

Drug research and approvals for hypercalcemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 19, 2026, 8 studies of hypercalcemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, FDA has 7 approved and 1 open orphan designations naming it, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 8
  • Trials authorized in Canada: 1
  • FDA orphan approvals: 7
  • EU medicines: 3

Recruiting now

Newest posted first, of 8 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 8

Phase 1 or earlier 1

  • RifampinBacterial DNA-directed RNA polymerase inhibitor

How its trials ended

47 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 12 whose ending is known, 33% met their primary endpoint, 0% missed it and 67% stopped early.

  • Completed, result not reported1838%
  • Status unknown919%
  • Ongoing817%
  • Stopped: other or unclear511%
  • Met its primary endpoint49%
  • Stopped: enrollment or feasibility24%
  • Stopped: funding12%

Trials authorized in Canada

Newest first; search them all in Canada trials
AuthorizedTrialSponsorStatus
Sep 26, 2017Rifampin to reduce elevated levels of blood and urine calcium in patients with idiopathic infantile hypercalcemiaRifampinThe Hospital for Sick ChildrenClosed

FDA orphan designations

Approved first, then open designations, newest first
Dec 5, 2014XgevaTo treat hypercalcemia of malignancy refractory to biphosphonate therapy.Amgen, Inc.Approved
Nov 21, 2014SensiparTreatment of hypercalcemia in adult patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of…Amgen, Inc.Approved
Feb 25, 2011SensiparTreatment of severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomyAmgen, Inc.Approved
Mar 8, 2004SensiparTreatment of hypercalcemia in patients with parathyroid carcinomaAmgen, Inc.Approved
Aug 20, 2001Zometa, ZabelTreatment of hypercalcemia of malignancy.Novartis Pharmaceuticals Corp.Approved
Jan 17, 1991GaniteTreatment of hypercalcemia of malignancy.Solopak Pharmaceutical Co.Approved
Apr 21, 1987DidronelTreatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.MGI Pharma, Inc.Approved
Jun 16, 1993Disodium clodronateTreatment of hypercalcemia of malignancy.Discovery Experimental & Development, Inc.Designated

Medicines authorised in the EU

Newest first
Jan 16, 2014Zoledronic Acid AccordZoledronic acid · genericAccord Healthcare S.L.U.EMA ↗
Jan 21, 2011IasibonIbandronic acid · genericPharmathen S.A.EMA ↗
Jun 25, 1996BondronatIbandronic acidAtnahs Pharma Netherlands B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.